Teleflex Incorporated (TFX) Stock Price
TFXStock
$130.43+5.29%52W
Market Cap$5.53B
P/E77.07x
PEG Ratio0.16
Div yield0.62%
Beta0.85
TFX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-5.74%
Price vs S&P 500 (4W)5.84%
PEG Ratio0.16
VGM Score47.60
P/E Ratio (Annual)77.07x
Indicated Dividend Yield (Annual)0.62%
TFX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.28 | $1.76 | +37.38%(+$0.48) | |
| Q1 2026 | $1.21 | $1.39 | +14.50%(+$0.18) | |
| Q4 2025 | $3.75 | $1.93 | -48.51%(-$1.82) | |
| Q3 2025 | $3.38 | $3.67 | +8.61%(+$0.29) | |
| Q2 2025 | $3.37 | $3.73 | +10.83%(+$0.36) |
TFX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.41
3.47
3.47
3.47
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
TFXTeleflex Incorporated | B | F | B | 2.1x | -4.7% | 53.8% | -11.7% | $130.43 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Teleflex Incorporated
Teleflex designs and manufactures medical devices for hospitals and healthcare providers in critical-care applications including anesthesia, emergency medicine, interventional procedures, and vascular access. Operating globally across Americas, EMEA, and Asia Pacific, the company derives the majority of its revenue from North America. Its products enhance clinical outcomes, improve safety, and reduce procedural costs across specialties including the UroLift system for interventional urology, interventional cardiology and radiology, and surgery.